Drugmaker AstraZeneca targets 2024 growth
AstraZeneca expects to boost 2024 revenue and profit on the back of its blockbuster cancer drugs, but lower than expected fourth-quarter profit dragged the London-listed drugmaker's shares down more than 5% today.
Business
• 08 Feb 24
